SCM
CLDX icon

Silverarc Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Silverarc Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-36,000
Closed -$971K – 85
2022
Q2 		$971K Buy
+36,000
New +$1.05M 0.3% 56

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Silverarc Capital Management's CLDX Position: Q2 2026 in Review

Silverarc Capital Management sold out of Celldex Therapeutics (CLDX) in Q2 2026, closing a stake of 178,378 shares — an estimated $5.66M sold.

Silverarc Capital Management first reported a position in CLDX in Q4 2020 and held it in 20 quarters. The position peaked at $13.9M in Q2 2024. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Silverarc Capital Management reported no remaining Celldex Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Silverarc Capital Management sold 178,378 Celldex Therapeutics shares in Q2 2026, an estimated $5.66M.
  • Silverarc Capital Management first reported a position in Celldex Therapeutics in Q4 2020 and held it in 20 quarters.
  • Silverarc Capital Management's Celldex Therapeutics position peaked at $13.9M in Q2 2024.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.